Octreotide Dose Escalation as Pr Octreotide Dose Escalation as Primary and Secondary Therapy for Patients with Acromegaly A Clinical Study Abbas Mahdi Rahmah* FRCP, Nizar Shawky Shawky CABM, Noor Thair Tahir* PhD
Background: Acromegaly is known to reduce life expectancy. Predictors of survival are growth hormone (GH) 2.5 µg/L and normal insulin like growth factor-1. Objective: To evaluate efficacy of dose escalation of octreotide – long – acting – repeatable from 20 to 40 mg every 28 days intramuscularly in a sample of acromegalic patients whose biomarkers fail to drop down to the recommended targets after using octreotide – long – acting – repeatable for a year (20 mg) every 28 days.
Methods: An analytic, observational, open and prospective study. Seventeen acromegalic patients using octreotide – long – acting – repeatable 20 mg every 28 days fail to reduce growth hormone < 2.5 µg/L and insulin like growth factor-1 to the recommended level. The dose was doubled for six months, in order to achieve the recommended goals of growth hormone and insulin like growth factor-1. The patients were divided into two groups in each occasion: - Those harbouring microadenoma versus macroadenoma. - Patients with previous hypophysectomy versus those with no prior hypophysectomy. - Males versus females. - Those with a disease duration ≥ 10 years versus those with a disease duration of < 10 years. - Sonogram of the abdomen and oral glucose tolerance test were done prior to recruitment and at the end of the study.
Results: Growth hormone and insulin like growth factor-1 levels drop by 62.5% and 37%, respectively, on 40 mg monthly octreotide – long – acting – repeatable in those who underwent hypophysectomy and by 63.5% and 38%, respectively, in those with no history of hypophysectomy. Those two biomarkers drop by 61.4% and 35.3% in those harboring macroadenoma and by 70% and 42% in those harboring microadenoma. The decrement of growth hormone, and insulin like growth factor-1 was found to be 70% and 41.9%, respectively, in those with disease duration ≥ 10 years and by 66.9% and 34.8% in those with disease duration < 10 years. In males these biomarkers drop by 63% and 38% while in females, they drop by 59% and 31%, 6 months after doubling the dose of octreotide – long – acting – repeatable. No patient developed impairment of glucose tolerance or gall stones at the end of study period.
Conclusion: Increasing the dose of octreotide – long – acting – repeatable from 20 to 40 mg every 28 days in acromegalic patients, resistant to the conventional dose of octreotide – long – acting – repeatable is found to be fruitful in reducing growth hormone and insulin like growth factor-1 by significant percentage irrespective of gender, disease duration, previous hypophysectomy or harboring micro or macro adenoma.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Share — copy and redistribute the material in any medium or format
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.